It was previously reported that various inflammation-based prognostic scores, such as C-reactive protein (CRP), Glasgow prognostic score (GPS), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) might be useful for predicting survival in patients with a malignant neoplasm [17–20]. This evidence concerns the gene CRP and cancer.